Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350

Joan Fortuny, Alicia Gilsenan (Lead / Corresponding author), Miguel Cainzos-Achirica, Oscar F. Cantero, Robert W. V. Flynn, Luis Garcia-Rodriguez, Bianca Kollhorst, Pär Karlsson, Love Linnér, Thomas M. MacDonald, Estel Plana, Ana Ruigómez, Tania Schink, Ryan Ziemiecki, Elizabeth B. Andrews

Research output: Contribution to journalArticle

1 Citation (Scopus)
126 Downloads (Pure)

Abstract

Introduction: Given prior safety experience with other 5-HT4 agonists for chronic constipation, an observational, population-based cohort study in five data sources from Germany, Sweden, and the UK was conducted to evaluate the cardiovascular safety of prucalopride.

Objectives: Our objective is to describe the methods and resulting comparability of cohorts in a multi-database, multinational study of prucalopride initiators and polyethylene glycol 3350 (PEG) initiators following a harmonized protocol.

Methods: Prucalopride initiators were matched on age, sex, and index date to PEG initiators (1:5 ratio). Study exposures, cardiovascular risk factors, and other covariates were identified from healthcare utilization codes harmonized across databases. Cardiovascular outcomes were identified using database-specific algorithms based on diagnosis codes. The propensity score (PS) in each database was estimated using logistic regression, with prucalopride versus PEG as the outcome and including clinically relevant variables associated with major adverse cardiovascular events.

Results: In total, 12,030 prucalopride initiators and 59,985 PEG initiators were identified. After matching and trimming, cohorts from the UK and Sweden were well-balanced for cardiovascular risk factors and cancer. However, in Germany, PEG initiators remained older and sicker than prucalopride initiators. The prevalence of these characteristics also differed from those in the UK and Sweden. The pooled analyses included only data from the UK and Sweden.

Conclusions: Matching, trimming, and PS stratification yielded comparable cohorts in four of five data sources. Use of these methods could not achieve balance for key covariates within the German cohort, likely due to reimbursement differences in Germany.

Original languageEnglish
Pages (from-to)1167-1177
Number of pages11
JournalDrug Safety
Volume42
Issue number10
Early online date27 May 2019
DOIs
Publication statusPublished - Oct 2019

Fingerprint Dive into the research topics of 'Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350'. Together they form a unique fingerprint.

  • Profiles

    No photo of Thomas MacDonald

    MacDonald, Thomas

    Person: Academic

    Cite this

    Fortuny, J., Gilsenan, A., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., Kollhorst, B., Karlsson, P., Linnér, L., MacDonald, T. M., Plana, E., Ruigómez, A., Schink, T., Ziemiecki, R., & Andrews, E. B. (2019). Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350. Drug Safety, 42(10), 1167-1177. https://doi.org/10.1007/s40264-019-00836-z